Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.82 |
| ▸ | GIPR | P48546 | 13/20 | 0.82 |
| ▸ | VIPR2 | P41587 | 4/20 | 0.73 |
| ▸ | GLP1R | P43220 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.67 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.67 |
| ▸ | DUSP2 | Q05923 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2642936 | 1.00 | GCGR (0.82) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2790901 | 1.00 | GCGR (0.82) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2643626 | 0.95 | GCGR (0.80) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL928959 | 0.94 | GCGR (0.87) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2794351 | 0.94 | GCGR (0.87) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2643445 | 0.93 | GCGR (0.74) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2642981 | 0.93 | GCGR (0.83) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2643137 | 0.92 | GCGR (0.72) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL16830706 | 0.92 | GCGR (0.69) | GCGRGIPRVIPR2GLP1RKCNH2 | |
| SCHEMBL2649967 | 0.92 | GCGR (0.77) | GCGRGIPRVIPR2GLP1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974413-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2022-03-30 | — | — | EP | disclosed |
| EP-3082786-B1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | MERCK SHARP & DOHME CORP. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | MERCK SHARP & DOHME CORP. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2928497-B1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | MERCK SHARP & DOHME (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-2928497-B1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | MERCK SHARP & DOHME (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9834563-B2 | Antidiabetic substituted heteroaryl compounds | MERCK SHARP & DOHME CORP. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170216250-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | Merch Sharp & Dohme Corp. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216250-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | Merch Sharp & Dohme Corp. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-06-15 | — | — | US | disclosed |
| US-20150320724-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2015-11-12 | — | — | US | disclosed |
| WO-2014093189-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-8455520-B2 | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110039860-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. | 2011-02-17 | — | — | US | disclosed |
| US-20110003849-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2011-01-06 | — | — | US | disclosed |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2007047676-A1 | PYRAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PARMEE EMMA R | 2007-04-19 | — | — | US | disclosed |
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PARMEE EMMA R | 2007-04-19 | — | — | US | disclosed |
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PARMEE EMMA R | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088070-A1 | Pyrazole derivatives, compositions containing such compounds and methods of use | PC, GOT2, PNLIP | GCGR 188/4885GIPR 205/4885VIPR2 1017/4885 |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GCGR 1560/4885GIPR 1773/4885VIPR2 1040/4885 |
| US-20170166578-A1 | ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS | GPR119, GPR65, GPR55 | GCGR 6/4885GIPR 8/4885VIPR2 597/4885 |
| US-11077092-B2 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 98/4885 |
| US-20110003849-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GCGR 1489/4885GIPR 1755/4885VIPR2 1091/4885 |
| US-20170216250-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 98/4885 |
| US-20110039860-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GCGR 1611/4885GIPR 2314/4885VIPR2 1084/4885 |
| US-20150320724-A1 | METHODS OF TREATING DIABETES BY ADMINISTERING A GLUCAGON RECEPTOR ANTAGONIST IN COMBINATION WITH A CHOLESTEROL ABSORPTION INHIBITOR | GLP1R, GCGR, GIPR | GCGR 2/4885GIPR 3/4885VIPR2 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.